Answers are grounded in this paper and cite their sources.
The HIV response in South Africa is at a critical moment. External financing is contracting, treatment and viral suppression gaps remain, condom use has declined, behavioural programming is limited, and new prevention technologies are being rolled out. The decisions made now about allocating constrained resources define lives saved. The South African HIV Investment Cases (2016, 2021, 2023 and 2025) use mathematical modelling to identify the combinations of interventions that will deliver the greatest health benefit for available resources. This brief examines how the scope of these Investment Cases has changed over time and what that means for HIV prevention policy. Two issues arise. Firstly, the range of HIV prevention options considered has narrowed, with many interventions now excluded from analysis. The 2016 Investment Case evaluated social and behaviour change communication campaigns, condom education, and critical enablers (social and structural responses such as gender-based violence prevention, support for girls to remain in school, and cash transfers), alongside biomedical interventions including HIV testing, treatment, medical male circumcision, and pre-exposure prophylaxis. The analysis recommended scaling up a communication campaign to encourage HIV testing and discourage multiple sexual partnerships. From 2021 onward, communication campaigns and condom education were omitted, and structural enablers were no longer included. By 2025, none of these interventions had been reinstated, and no contemporary behavioural alternatives were assessed. As a result, key determinants of HIV transmission—including condom promotion, partnership patterns, and age at sexual debut—continue to be represented in epidemiological models but are no longer independently evaluated as potential investment pathways. Declining condom use among young people is not addressed by options to rebuild condom demand. Secondly, the published analyses do not consistently explain how different forms of uncertainty are applied to modelled options for inclusion, scenario analysis or exclusion. Although hypothetical interventions to improve antiretroviral therapy (ART) coverage are included in the 2025 Investment Case, strategies to enhance viral suppression among people already receiving treatment have not been independently assessed. Lenacapavir has been incorporated based on clinical trial evidence, despite uncertainties about real-world implementation, whereas behavioural prevention options have not been similarly examined through plausible scenarios. These decisions directly influence the range of investments available for policy consideration. A reduced set of options limits policy choices, affecting public expenditure, HIV infection rates, and the potential to extend healthy lives. The documented process for selecting and reviewing interventions has also narrowed, from a broad multi-sectoral consultation in 2016 to smaller review committees and technical working groups carried through into 2025. In response to these findings, a broader and multidisciplinary reassessment of HIV prevention investments, including behavioural prevention, is recommended. Particular emphasis should be placed on addressing condom demand and comparing treatment improvements and emerging technologies on a common basis. Evidence-informed priority-setting also requires transparent intervention selection, explicit treatment of different forms of uncertainty, broad participation and independent review.
No takes yet. Share an insight, caveat, or question.
Warren Parker (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: